Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
FEC-DocGemzar adjuvant chemotherapy · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| AA-BA | EXPERIMENTAL | FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 5 years |
| AB-BA | EXPERIMENTAL | FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 5 years |
| AA-BB | EXPERIMENTAL | FEC-DocGemzar adjuvant chemotherapy; zoledronic acid i.v. 2 years |
| AB-BB | ACTIVE_COMPARATOR | FEC-Doc adjuvant chemotherapy; zoledronic acid i.v. 2 years |
| Name | Type | Description |
|---|---|---|
| FEC-DocGemzar adjuvant chemotherapy | DRUG | - |
| FEC-Doc adjuvant chemotherapy | DRUG | - |
| Zoledronic acid i.v. 2 years | DRUG | - |
| Zoledronic acid i.v. 5 years | DRUG | - |
Inclusion Criteria: * Primary epithelial invasive carcinoma of the breast pT1-4, pM0 * Histopathological proof of axillary lymph node metastases (pN1-3) or high risk pN0/NX, defined as: 'pT ≥ 2 or histopathological grade 3 or age ≤ 35 or negative hormone receptor status' * Complete resection the pr...
FEC-DocGemzar adjuvant chemotherapy is used for breast neoplasms, specifically as an adjuvant treatment for breast cancer. It is being studied in a Phase 3 clinical trial in Germany. The drug is developed by Eli Lilly and Company.
FEC-DocGemzar adjuvant chemotherapy is developed by Eli Lilly and Company, which trades under the ticker LLY. The company is conducting a Phase 3 clinical trial for this adjuvant chemotherapy in breast cancer patients.
FEC-DocGemzar adjuvant chemotherapy is in Phase 3 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed with 3,754 female participants.
FEC-DocGemzar adjuvant chemotherapy is associated with clinical trial NCT02181101, titled 'Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-Trial'. This Phase 3 trial was completed in Germany and enrolled 3,754 female patients with breast neoplasms.
Yes, FEC-DocGemzar adjuvant chemotherapy is the same as the gemcitabine-docetaxel combination. The clinical trial NCT02181101 studies this combination as adjuvant treatment for breast cancer, along with extended bisphosphonate and surveillance.